A new dinuclear platinum complex with a nitrogen-containing geminal bisphosphonate as potential anticancer compound specifically targeted to bone tissues.

Abstract

The paper describes the synthesis and characterization of a new platinum dinuclear complex (2) bearing a nitrogen-containing geminal bisphosphonate (NBP, 1), structurally related to the commercial drug risedronate. NBPs themselves have shown in quite a few cases to be endowed with anticancer activity, therefore the new platinum complex has two potential antitumor moieties (the NBP ligand and the platinum residue) and could have high affinity for bone tumors or metastases (due to the presence of NBP). The free bisphosphonate (1) has been crystallized by a sol-gel method and characterized by X-ray diffraction analysis. The platinum complex (2) has been found to have a dinuclear structure with the bisphosphonate bridging two platinum moieties in a W conformation.

• Authors: Nicola Margiotta, Francesco Capitelli, Rosa Ostuni, Giovanni Natile
• Journal: Journal of inorganic biochemistry (J Inorg Biochem) Vol. 102 Issue 12 Pg. 2078-86 (Dec 2008) ISSN: 1873-3344 [Electronic] United States
• PMID: 18760482 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Bone Density Conservation Agents
• Diphosphonates
• Organoplatinum Compounds
• bis(ethylenediamine)(1-hydroxy-1-(pyridinium-4-yl)methane-1,1-bisphosphonate)diplatinum(II)
• Risedronic Acid
• Etidronic Acid

Topics

• Antineoplastic Agents (chemical synthesis, chemistry, pharmacology)
• Bone Density Conservation Agents (chemistry)
• Bone Neoplasms (metabolism)
• Cell Line, Tumor
• Crystallization
• Crystallography, X-Ray
• Diphosphonates (chemical synthesis, chemistry, pharmacology)
• Etidronic Acid (analogs & derivatives)
• Humans
• Organoplatinum Compounds (chemical synthesis, chemistry, pharmacology)
• Risedronic Acid